MARKET

NXTC

NXTC

Nextcure
NASDAQ
2.230
+0.295
+15.25%
After Hours: 2.250 +0.02 +0.90% 19:47 03/28 EDT
OPEN
1.900
PREV CLOSE
1.935
HIGH
2.280
LOW
1.820
VOLUME
1.02M
TURNOVER
0
52 WEEK HIGH
2.280
52 WEEK LOW
0.9800
MARKET CAP
62.22M
P/E (TTM)
-0.9897
1D
5D
1M
3M
1Y
5Y
Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PyX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. In September 2023, the company's stock was trading below cash and data was expected in early 2024.
Seeking Alpha · 1d ago
Weekly Report: what happened at NXTC last week (0318-0322)?
Weekly Report · 4d ago
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
NextCure (NASDAQ:NXTC) has a negative free cash flow of US$54m over the last year. NextCure's cash burn relative to its market capitalisation is higher than the company's market value. The company has a 2.0 year runway to burn through its cash reserves. We look at Nextcure's rate of cash burn to see how the company is expected to grow in the future.
Simply Wall St · 5d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The company's market cap stands at $8.0 billion. Masimo shares rose 12.48% and NextCure shares declined by 9.5% during the same session.
Benzinga · 6d ago
NextCure Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 6d ago
NextCure Price Target Raised to $8.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Maintains Buy on NextCure, Raises Price Target to $8
Benzinga · 6d ago
Promising Clinical Trial Results for NextCure’s NC410 Bolster Buy Rating
TipRanks · 03/22 10:17
More
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.

Webull offers NextCure Inc stock information, including NASDAQ: NXTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NXTC stock methods without spending real money on the virtual paper trading platform.